Your patient is at goal. LDL 51 on rosuvastatin and ezetimibe, apoB checked, blood pressure fine, A1c 5.8. Triglycerides 240, which you noted and did not act on, because triglycerides of 240 are the wallpaper of obesity medicine.

There is a number on that same panel you did not calculate. It took no additional blood, no send-out, and no prior authorization, and in the trial data it still tracks events when the LDL you spent the visit optimizing no longer does.

Remnant cholesterol is the cholesterol content of triglyceride-rich lipoproteins: VLDL, IDL, and chylomicron remnants. You calculate it by subtracting HDL-C and LDL-C from total cholesterol, and there is nothing more to it than that. Every lipid panel you have ever ordered already contains the inputs, and essentially no lab reports the output.

One caveat before you start subtracting. If your lab still calculates LDL-C by the Friedewald equation, remnant cholesterol collapses to exactly TG divided by 5 and tells you nothing your triglyceride did not already say. For the number to carry independent information you need a direct LDL-C or a Martin-Hopkins calculation, which most large labs have now adopted. It is worth finding out which one your lab reports, because that single phone call determines whether the rest of this article applies to your panels.

The biology behind why it matters comes down to one fact that took the field an embarrassingly long time to internalize: most cells can catabolize triglyceride, but no cell can catabolize cholesterol. So when a triglyceride-rich particle gets partially delipidated in circulation, the triglyceride goes away and the cholesterol stays behind, riding in a smaller, denser remnant that is small enough to enter the arterial wall and is retained there.

That reframes the whole triglyceride conversation, because triglycerides themselves are probably not the atherogenic agent at all. They are a marker for the number of cholesterol-carrying particles you were not counting. It also explains why triglycerides look like a weak, inconsistent risk factor in some analyses and a strong one in others: the signal is real, but you have been measuring the wrong thing on the particle.

The RACING post hoc is the analysis that should unsettle anyone who treats an LDL at goal as the end of the conversation.

Investigators took 3,348 patients with established ASCVD, all on statin-based therapy, and looked at their lipid profile one year after randomization. They split the cohort into tertiles by on-treatment remnant cholesterol: at or below 14 mg/dL, 14 to 20.5, and above 20.5. At three years, the primary composite occurred in 7.5% of the low tertile, 10.3% of the intermediate, and 11.0% of the high, p=0.009 across tertiles. Remnant cholesterol above the 17 mg/dL median carried a hazard ratio of 1.42 (95% CI 1.14 to 1.78, p=0.002).

The finding that matters most, though, is what the same analysis showed about LDL, because achieving a level below 55 or below 70 was not associated with the primary endpoint at all.

Read that carefully and do not over-read it. This is a post hoc analysis of a trial designed to answer a different question, on-treatment lipid values are not randomized, and confounding by indication is a live concern. None of it means LDL lowering has stopped working, since forty years of randomized evidence says otherwise and nothing here argues for backing off statins.

What it does suggest is that in a population where LDL has already been driven low, the remaining variance in risk is not sitting in LDL anymore. You have squeezed that lever most of the way. The Copenhagen General Population Study points the same direction from a different angle: across 25,480 people followed a median of eleven years, VLDL cholesterol accounted for 50% of the myocardial infarction risk attributable to apoB-containing lipoproteins, while IDL and LDL together accounted for 29%.

And the number almost nobody quotes from that paper is the one that settles the argument. VLDL triglyceride, the fat itself, the thing on your panel with a name everyone recognizes, accounted for 8% of the risk, with a confidence interval that crossed zero. The cholesterol inside the particle did the damage, while the triglyceride was only ever the address label.

This is what residual risk actually looks like. It is not mysterious and it is not inflammation alone, which is a lesson the IL-6 program delivered recently and expensively.

On June 24, 2026, six days ahead of its PDUFA date, the FDA approved olezarsen for severe hypertriglyceridemia, defined as triglycerides at or above 500 mg/dL. It had already been approved in December 2024 for familial chylomicronemia syndrome. The new indication opens it to a population Ionis estimates at more than three million people in the United States, roughly a million of whom are considered high risk.

Olezarsen is an antisense oligonucleotide conjugated to a triantennary GalNAc ligand, which delivers it to hepatocytes, where it suppresses production of apolipoprotein C-III. ApoC-III inhibits lipoprotein lipase and impedes hepatic uptake of triglyceride-rich particles, so removing it accelerates clearance. It comes as a monthly subcutaneous autoinjector, starting at 50 mg in severe hypertriglyceridemia with titration to 80 mg if further reduction is warranted, and 80 mg is the fixed dose in FCS.

The pivotal program was CORE-TIMI 72a and CORE2-TIMI 72b, run through the TIMI Study Group: roughly 1,060 adults with severe hypertriglyceridemia on background lipid-lowering therapy, median baseline triglycerides of 793 mg/dL, randomized to olezarsen 50 mg, 80 mg, or placebo monthly for 12 months. Nearly half the pooled CORE and CORE2 population started above 880 mg/dL.

Placebo-adjusted triglyceride reductions at six months ran 49% to 63% at 50 mg and 55% to 72% at 80 mg, sustained through 12 months. At a year, 86% of treated patients were below 500 mg/dL, against 35% on placebo.

The pancreatitis result is the one that matters. Acute pancreatitis events fell with a pooled rate ratio of 0.15, a 95% confidence interval of 0.05 to 0.40, and a p value below 0.001. That is an 85% relative reduction, and it is the first time any triglyceride-lowering therapy has demonstrated a reduction in a hard clinical endpoint in this population.

The absolute numbers are the ones to quote to a patient. In the high-baseline subgroup presented at EAS 2026, the absolute reduction was roughly 12 pancreatitis events per 100 patient-years, which works out to treating about nine patients for a year to prevent one attack. Across the full pooled population the number needed to treat was 20; in patients with both baseline TG above 880 and a prior episode, it was 4. For a condition where a single attack can mean an ICU bed and a necrosectomy, those are not marginal numbers.

Tolerability was good, and I want to be careful about how good. Serious adverse events were numerically fewer on drug than on placebo, but the difference was not statistically significant, so the accurate statement is that no safety signal separated the groups rather than that the drug was protective. Injection site reactions were the main treatment-emergent finding, occurring in 12% to 18% of patients, mild and dose-related. Hypersensitivity reactions including urticaria and facial swelling appear in the label and warrant counseling.

Three findings deserve more attention than the press releases gave them. Hepatic fat fraction rose on MRI in a dose-dependent way, with about 40% of patients on 80 mg showing an absolute increase of five percentage points or more at 12 months, and nobody knows yet what that means over a span of years. Transaminase elevations occurred in 3% to 4%, more often at the higher dose, and HbA1c rose about 0.25%. None of this is disqualifying in a patient whose alternative is recurrent pancreatitis, but all three belong in the conversation you have before writing the prescription, and all three are worth watching as the population using this drug widens from a few thousand people with FCS to a few million with severe hypertriglyceridemia.

Here is where the field gets ahead of itself, and where the discipline you applied to Lp(a) needs to apply again.

Pancreatitis prevention is not cardiovascular prevention, and treating the two as interchangeable is the error this section exists to head off. They are different endpoints in different populations driven by different biology: triglycerides above 500 cause pancreatitis mechanically, through chylomicronemia, while remnant cholesterol drives atherosclerosis through arterial retention. A drug can be excellent at the first and do nothing whatsoever for the second.

We already have the cautionary trial. PROMINENT randomized 10,497 patients with type 2 diabetes, triglycerides of 200 to 499 mg/dL, and HDL-C at or below 40, nearly all of them on statins, to pemafibrate or placebo. Triglycerides fell 26.2% and remnant cholesterol fell 25.6%, and the hazard ratio for cardiovascular events came out at 1.03, with a 95% confidence interval of 0.91 to 1.15 and a p value of 0.67.

A quarter of the triglycerides were gone, and not a single event was prevented.

The explanation is sitting in the same abstract, and it is the most useful number in this entire article. Pemafibrate lowered triglycerides while apoB rose 4.8% and LDL-C rose roughly 12%, which means the particle count went up even as the fat inside those particles came down, and the events tracked the particles rather than the fat. If you carry one sentence out of this piece, make it this one: the target is atherogenic particles, not the triglyceride number. Any agent that moves triglycerides without moving apoB should be assumed inert for cardiovascular outcomes until a trial says otherwise.

Here is where this article changed while I was writing it. The obvious objection to the PROMINENT lesson is that olezarsen is not a fibrate. ApoC-III inhibition does lower apoB, which is exactly the property pemafibrate lacked, and that is the honest mechanistic case for expecting a different result.

That case has now been partially tested. ESSENCE-TIMI 73b randomized 1,349 patients with moderate hypertriglyceridemia at elevated cardiovascular risk, and olezarsen delivered on every count: triglycerides down about 56%, more than 85% of patients under 150 mg/dL, and apoB down roughly 16% against placebo. Everything the mechanism promised, it produced.

Then the coronary CTA substudy read out at ACC 2026. Non-calcified plaque volume at 12 months showed a placebo-adjusted difference of +2.98%, with a 95% CI of −3.4 to 9.3 and a p value of 0.36, and there was no effect on low-attenuation plaque, calcified plaque, or total plaque either. Triglycerides had fallen by half and apoB by a sixth, and the artery did not notice.

Read that with the appropriate caution in both directions. Plaque volume is a surrogate, twelve months is short, and imaging substudies have missed before in drug classes that later prevented events. ESSENCE was never designed or powered for cardiovascular outcomes, so this is not a failed outcomes trial so much as the absence of the early signal you would have liked to see. The investigators said as much themselves, and a dedicated cardiovascular outcomes trial has not yet reported.

But notice what has happened to the argument. Six months ago the case for apoC-III inhibition as a cardiovascular therapy rested on mechanism plus a favorable apoB response, and that apoB response has now arrived without the plaque following it. The field is in a materially weaker position than it occupied before, and you should update accordingly.

Calculate remnant cholesterol on every lipid panel. Total cholesterol minus HDL-C minus LDL-C costs nothing and takes five seconds. Roughly 30 mg/dL is where the trial cohorts start separating, with PREDIMED using 30 and an ACCORD analysis using 31, while the RACING on-treatment median of 17 mg/dL is the more aggressive benchmark in secondary prevention. Be honest with yourself that these are cohort-derived cut-points rather than guideline targets, because neither the 2025 ESC/EAS focused update nor the 2026 ACC/AHA dyslipidemia guideline sets a remnant cholesterol goal.

Use non-HDL cholesterol as the practical shortcut. Non-HDL captures LDL plus remnants in a single number, it is already on most panels, and unlike remnant cholesterol it has actual guideline targets behind it. It also sidesteps the weakness that runs underneath everything else on this list: non-HDL is total cholesterol minus HDL-C, so it never touches an LDL-C value at all, and it stays trustworthy in exactly the high-triglyceride setting where a calculated LDL-C is least reliable. ESC/EAS secondary goals are under 85 mg/dL in very high risk, under 100 in high risk, and under 130 in moderate. The 2026 ACC/AHA guideline brought explicit LDL-C and non-HDL-C goals back and added selective apoB measurement for exactly this situation, meaning residual risk assessment in diabetes, high triglycerides, or established ASCVD once the primary goals are met. If you change one habit after reading this, make it working the non-HDL number rather than stopping at LDL.

Get an apoB. When triglycerides are up, a calculated LDL-C is the least trustworthy number on the panel, and it is worth sitting with the fact that remnant cholesterol is derived from that same value. ApoB counts atherogenic particles directly and does not care how much fat is inside them, which makes it the measurement the two calculated numbers are only ever approximating. If remnant cholesterol is elevated and you are deciding how hard to push, this is the test that settles it.

Treat the cause first, and in your practice that is usually metabolic. Insulin resistance, visceral adiposity, alcohol, and uncontrolled diabetes drive triglyceride-rich lipoprotein production. Weight reduction and glycemic control move this lipid fraction substantially, and incretin therapy lowers triglycerides meaningfully. That is unglamorous and it is where most of the yield is.

Reserve olezarsen for what it was approved for. Triglycerides at or above 500, and above all the patient with recurrent pancreatitis. That is a genuinely underserved population who have been managed with fibrates, fish oil, and dietary fat restriction for decades with modest results. It is not a drug for the patient at 240 with an LDL at goal.

Do not tell patients this prevents heart attacks. It prevents pancreatitis, and the accurate claim is the one worth making.

Remnant cholesterol is the most underused number in preventive lipidology. It requires no new test, no new equipment, and no new billing code. It identifies residual risk in exactly the patients who look finished on paper, and it is elevated in most of the patients an obesity medicine practice sees, because the metabolic disease that drives weight drives this lipid fraction too.

Meanwhile the drugs have arrived, and they are better than anything we had. Olezarsen is a real advance for a real population, and the pancreatitis result is a hard endpoint honestly earned.

Just keep the two claims separate. We have a treatment for triglyceride-driven pancreatitis and it is a good one, but we do not have a treatment for triglyceride-driven atherosclerosis. PROMINENT showed what happens when you move the fat and not the particles, and ESSENCE showed that moving both is not automatically enough either. Until an outcomes trial reports, that is the whole of what we know.

The drug will be right for a few hundred of your patients, but the subtraction applies to all of them.

The patient described at the top is a composite. No individual patient is depicted.

Data current as of August 2026. Verify approval status, indications, and dosing against current prescribing information before acting on anything above.

Disclosure: The author is Chief Medical Officer of Vineyard, a telehealth obesity medicine practice.

REFERENCES

P.S. Both free one-pagers are live. The GLP-1 Evidence Cheat Sheet, twelve pivotal trials on one page. The Retatrutide Cheat Sheet, the triple agonist in plain numbers.

Following the latest trials? The live tracker is here: substance-over-noise.beehiiv.com/trials

Was this forwarded to you? Join {{active_subscriber_count}} readers and subscribe free.